You are here

COVID-19

New and Emerging Drug Classes That Will Outlast the Pandemic

New and Emerging Drug Classes That Will Outlast the Pandemic

BioSpace

Flag link:

Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?

Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?

Fierce Biotech

Gilead Sciences

Acrotech Biopharma

Flag link:

Pfizer Criticizes Sudden Change in Coronavirus Vaccine Dosing Regime in the U.K.

Pfizer Criticizes Sudden Change in Coronavirus Vaccine Dosing Regime in the U.K.

Motley Fool

Flag link:

China’s Sinopharm Claims COVID-19 Vaccine has 79% Efficacy

China’s Sinopharm Claims COVID-19 Vaccine has 79% Efficacy

BioSpace

clinical trials

Flag link:

Pfizer and BioNTech to offer COVID vaccine to volunteers who got placebo

Pfizer and BioNTech to offer COVID vaccine to volunteers who got placebo

Yahoo/Reuters

clinical trials

Flag link:

Operation Warp Speed Slow to Ramp Up COVID-19 Vaccine Distribution

Operation Warp Speed Slow to Ramp Up COVID-19 Vaccine Distribution

BioSpace

Operation Warp Speed

Flag link:

Moderna in talks with South Korea to supply 40 million doses of Covid-19 vaccine

Moderna in talks with South Korea to supply 40 million doses of Covid-19 vaccine

Pharmaceutical Business Review

Moderna Therapeutics

Flag link:

AstraZeneca's COVID-19 vaccine gets the green light in the UK

AstraZeneca's COVID-19 vaccine gets the green light in the UK

Biopharma Reporter

Flag link:

Pfizer and BioNTech Supplying 100 Million Additional Doses of Coronavirus Vaccine to European Union

Pfizer and BioNTech Supplying 100 Million Additional Doses of Coronavirus Vaccine to European Union

Motley Fool

Flag link:

U.S. Department of Defense Awards Moderna $1.97 Billion COVID-19 Vaccine Contract

U.S. Department of Defense Awards Moderna $1.97 Billion COVID-19 Vaccine Contract

BioSpace

Moderna Therapeutics

government contracts

Department of Defense

Flag link:

Biden joins public health experts in expressing dismay as early days of COVID vaccine rollout in U.S. fall far short of expectations

Biden joins public health experts in expressing dismay as early days of COVID vaccine rollout in U.S. fall far short of expectations

Marketwatch

Flag link:

Regeneron says it will continue trial of COVID antibody cocktail as latest data show positive results

Regeneron says it will continue trial of COVID antibody cocktail as latest data show positive results

Marketwatch

Flag link:

UK expected to approve Oxford-AstraZeneca Covid vaccine this week

UK expected to approve Oxford-AstraZeneca Covid vaccine this week

CNBC

Flag link:

EU is asked to approve extra dose from Pfizer vaccine vials

EU is asked to approve extra dose from Pfizer vaccine vials

Yahoo/Reuters

Flag link:

Novavax Starts a Late-Stage Coronavirus Vaccine Clinical Trial

Novavax Starts a Late-Stage Coronavirus Vaccine Clinical Trial

Motley Fool

clinical trials

Flag link:

Why New Coronavirus Strains Could Boost Pfizer and Moderna's Fortunes

Why New Coronavirus Strains Could Boost Pfizer and Moderna's Fortunes

Motley Fool

Moderna Therapeutics

Flag link:

What if we captured the spirit and urgency of Covid-19 research to cure cancer?

What if we captured the spirit and urgency of Covid-19 research to cure cancer?

MedCity News

drug development

Flag link:

Moderna or Pfizer? Which Company Stands to Gain the Most From Vaccine Rollout

Moderna or Pfizer? Which Company Stands to Gain the Most From Vaccine Rollout

Motley Fool

Moderna Therapeutics

Flag link:

Therapeutics for ‘COVID-19 Long-Haulers’ Exploding onto the Scene as 2020 Ends

Therapeutics for ‘COVID-19 Long-Haulers’ Exploding onto the Scene as 2020 Ends

BioSpace

PureTech Health

COVID long-haulers

Flag link:

Merck signs $356M deal to supply US with experimental coronavirus drug

Merck signs $356M deal to supply US with experimental coronavirus drug

BioPharma Dive

government contract

Flag link:

Pages